ELOVL1 Antibody
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q9BW60 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 33,29 KDa |
Antigen Region | 120-149 aa |
Gene ID | 64834 |
---|---|
Other Names | Elongation of very long chain fatty acids protein 1, 3-keto acyl-CoA synthase ELOVL1, ELOVL fatty acid elongase 1, ELOVL FA elongase 1, Very-long-chain 3-oxoacyl-CoA synthase 1, ELOVL1, SSC1 |
Dilution | WB~~ 1:1000 |
Format | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol. |
Storage Conditions | -20℃ |
Name | ELOVL1 (HGNC:14418) |
---|---|
Synonyms | SSC1 |
Function | Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle (PubMed:29496980, PubMed:30487246). This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and monounsaturated acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis (PubMed:20937905). Indirectly inhibits RPE65 via production of VLCFAs. |
Cellular Location | Endoplasmic reticulum membrane {ECO:0000255|HAMAP-Rule:MF_03201, ECO:0000269|PubMed:20937905, ECO:0000269|PubMed:30487246}; Multi-pass membrane protein {ECO:0000255|HAMAP-Rule:MF_03201} |
Tissue Location | Ubiquitous. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Condensing enzyme that catalyzes the synthesis of both saturated and monounsaturated very long chain fatty acids (VLCFAs). Exhibits activity toward saturated C18 to C26 acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis. Indirectly inhibits RPE65 via production of VLCFAs.
References
Asadi A.,et al.Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
Lai C.-H.,et al.Genome Res. 10:703-713(2000).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Gregory S.G.,et al.Nature 441:315-321(2006).
Jakobsson A.,et al.Prog. Lipid Res. 45:237-249(2006).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.